BioWorld

April 7, 2003

Administration Won't Reimburse Failed Project BioShield Drugs

Senior Bush administration officials said companies contracted to develop biomedical countermeasures under Project BioShield would not receive full government payment until the FDA approved their products. (BioWorld Today) Read More

For Biotech, Speaker Declares: 'I've Never Seen A Better Time'

Palindromic DNA Sequence Allows p53 Target Genes To Kill Off Cancer Cells & Suppress Tumor Formation

Deltagen Gains At Least $10M In Private Financing Commitment

Correction

Memantine Improves Cognition When Combined With Aricept

Affymetrix Stock Falls Fast As It Projects Lower Product Revenue

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026